MS patients with active relapsing disease comparing two treatment plans
Treatments studied
Part of Brain & nervous system, Immune system & allergy clinical trials.
This Phase 3 study compares the best standard MS treatment (chosen by your doctors) versus an approach called autologous hematopoietic stem cell transplant (AHSCT) for people with highly active, treatment-resistant relapsing multiple sclerosis. It aims to see which option controls MS disease activity better and keeps you safer over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 to 55 when you start screening.
- You have relapsing multiple sclerosis (not primary progressive MS).
- Your MS has been very active recently despite treatment, with recent relapses and/or new MRI spots.
- Your brain MRI (and possibly spinal cord MRI) meets specific criteria showing active MS changes.
- You can potentially receive at least one “high-efficacy” MS medicine (cladribine, natalizumab, alemtuzumab, ocrelizumab, ofatumumab, ublituximab, or rituximab) and you’re eligible for that medicine.
- You can complete required immune and infection safety steps (COVID-19 vaccines/testing, chickenpox immunity, and no current infections).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether treating relapsing multiple sclerosis (RRMS) aggressively and early with a specific medication can slow disease progression. You may qualify if you were recently diagnosed, have had recent disease activity, and are willing to take a strong immunosuppressive drug with regular MRI monitoring.
This study tests different approved “disease-modifying” MS medicines (shots and pills) in adults with relapsing multiple sclerosis that is currently active. It mainly looks at outcomes based on how newly starting—or recently started—treatments are handled for people with recent relapses and mild disability.
This trial tests a new cell therapy called YTB323 for people with relapsing multiple sclerosis (RMS) that is still active despite strong treatments. The treatment aims to reset the immune system to stop attacks on nerves.
This Phase 3 trial tests the safety and effectiveness of a modified treatment plan using ublituximab for relapsing multiple sclerosis. It also studies how the drug behaves in the body and aims to improve disease control while monitoring side effects.
This study looks at how well different treatments, including bone marrow transplant, alemtuzumab, ocrelizumab, and ofatumumab, work for people with relapsing-remitting MS who have active disease. It will help doctors understand which therapy might slow disease progression best.
This trial tests if using your own stem cells can stop multiple sclerosis that keeps getting worse despite treatment. You would first receive a medication to reset your immune system, then get your stem cells back to help rebuild it.
Hear when a new Relapsing Multiple Sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.